Impella 2.5 improves survival in AMI with cardiogenic shock

Original title: The Use of Impella 2.5 in Severe Refractory Cardiogenic Shock Complicating and Acute Myocardial Infarction. Reference: Frederic Casassus et al. J Interv Cardiol. 2015 Feb;28(1):41-50.

The presence of cardiogenic shock is observed in 7% of patients undergoing acute myocardial infarction (AMI) with ST segment elevation and 2.5% of those with non-ST AMI. In this scenario inotropic have a poor response and the intra-aortic balloon pump (IABP) has been shown in multiple trials to be little or no effective.

22 patients who received the Impella 2.5 device and about to undergoing AMI with refractory cardiogenic shock were analyzed. Angioplasty was performed to culprit vessel and other vessels were treated in accordance with the decision of the surgeon. The involvement of other organs with SOFA and APACHE scores were analyzed prior to implantation of the device.

The average age of the population was 58 years and 40% had cardiopulmonary arrest prior to admission. The SOFA and APACHE scores were 9 and 30 points. All received inotropic; shock start mean time was 7 hours (1.8-19), IABP 54.6%. Angioplasty was successful in 86.4%. Half had cerebral anoxia injury, respiratory failure, and pulmonary edema. The third group showed severe acute deterioration of kidney function (eGFR <30). The Impella device was implanted using femoral approach successfully in all patients. There was a significant immediate improvement of ventricular filling pressures and ventricular function (27 ± 9% versus 43 ± 10%; p <0.0001). Peripheral perfusion improved after 48 hours of support. Impella 2.5 average time was 35.5 hours (21.5-57.8 hours).

Survival at 6 and 12 months was 59.1% and 54.5%. There was no stroke or vascular complications requiring surgery. 

Conclusion

The Impella 2.5 was used as a last alternative in patients who had cardiogenic shock and not responding to conventional treatment. The use of the device was favorable to short and medium term survival.

Editorial comment

This work covered a small population with a high mortality. Inotropic and IABP demonstrated its limited effectiveness. Ventricular assist devices are proving their benefit, giving an improvement in ventricular function, systemic injury and improving survival in the middle term with a low rate of complications related to the device. The development of these devices will help in this scenario.

Courtesy of Carlos Fava MD
Interventional Cardiologist
Buenos Aires – Favaloro Foundation

Carlos Fava

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...